GILD 10-K Annual Reports

Gilead Sciences, Inc. (GILD) reported total revenues of $28.8 billion for the year ended December 31, 2024, representing a 6% increase compared to the previous year. This growth was primarily driven by strong performance in its HIV, Oncology, and Liver Disease segments. However, net income attributable to Gilead saw a significant decrease of 92% to $480 million, largely due to substantial impairment charges related to Trodelvy's non-small cell lung cancer (NSCLC) program ($4.2 billion) and higher expenses from the CymaBay acquisition ($3.8 billion). The company is strategically focused on maximizing revenue growth, capitalizing on long-acting HIV therapies, and expanding its oncology portfolio. Key product highlights include continued demand for Biktarvy and expansion of Livdelzi's indication. Looking ahead to 2025, Gilead anticipates continued demand growth for its products, but expects this to be tempered by the effects of the Inflation Reduction Act, a decline in Veklury sales due to reduced COVID-19 hospitalizations, and the impact of a strengthening U.S. dollar. The company maintains a robust R&D pipeline and continues to pursue strategic collaborations and business development opportunities.

Gilead Sciences, Inc. reported total revenues of $27.1 billion for the fiscal year 2023, a slight decrease of 1% compared to 2022. This was primarily driven by a significant drop in Veklury (remdesivir) sales due to lower COVID-19 related hospitalizations, which was largely offset by robust growth in HIV and Oncology product sales. Net income attributable to Gilead increased by 23% to $5.7 billion, with diluted earnings per share rising 24% to $4.50. This improvement was largely due to lower impairment charges related to in-process research and development, reduced net unrealized losses on equity investments, and increased interest income. The company continues to strategically invest in its R&D pipeline through acquisitions and collaborations, particularly in oncology and inflammation. Key developments include expanded collaborations and the acquisition of smaller biotech firms to bolster its pipeline. Patent expirations for some key products are on the horizon, with major HIV products like Descovy and Vemlidy having U.S. patent expirations in 2031, and Biktarvy in 2033. The company also faces ongoing litigation, including challenges related to its HIV products and the sale of its PrEP medications, though recent legal outcomes have been favorable in some instances. Gilead maintains a strong liquidity position and continues to return capital to shareholders through dividends and share repurchases.

Gilead Sciences, Inc. (GILD) reported relatively flat total revenues of $27.3 billion for the fiscal year ended December 31, 2022, compared to the prior year. This stability was driven by growth in key areas like HIV, cell therapy, and Trodelvy, which offset a significant decline in Veklury (remdesivir) sales due to lower COVID-19 hospitalization rates. However, net income saw a substantial decrease of 26% to $4.6 billion, largely impacted by a $2.7 billion impairment charge related to Trodelvy's in-process R&D, higher R&D expenses, and a one-time charge in the prior year for a bictegravir litigation settlement that did not recur. Despite the net income decline, the company continues to invest in its pipeline through strategic acquisitions and collaborations, and returned value to shareholders through dividends and share repurchases.

Gilead Sciences, Inc. (GILD) reported solid revenue growth of 11% in 2021, reaching $27.3 billion. This was primarily driven by strong performance from Veklury (remdesivir), its treatment for COVID-19, which nearly doubled sales compared to the previous year. The company also saw continued growth in its Biktarvy franchise for HIV, and increased contributions from its oncology segment, particularly Trodelvy and its cell therapies (Yescarta and Tecartus). Despite these successes, Gilead faced headwinds from the loss of exclusivity for its Truvada and Atripla HIV medications in the U.S., leading to a 4% decrease in HIV product sales. The company also experienced a decline in HCV product sales due to reduced patient demand amid the COVID-19 pandemic. Gilead reported a significant increase in net income to $6.2 billion, a substantial improvement from $123 million in 2020, which was largely due to lower acquired in-process research and development (IPR&D) charges and favorable equity investment performance, partially offset by a large settlement charge related to bictegravir litigation. The company outlined a strategic focus on expanding its commercial portfolio and clinical pipeline, aiming to bring 10+ transformative therapies to patients by 2030. For 2022, Gilead anticipates product sales growth of 2-4% excluding Veklury, with expectations of continued recovery in its HIV business and growth in oncology. However, significant uncertainties remain regarding the trajectory of the COVID-19 pandemic and future Veklury sales.

Gilead Sciences, Inc. (GILD) reported total revenues of $24.7 billion for the year ended December 31, 2020, representing a 10% increase year-over-year, primarily driven by strong sales of Veklury (remdesivir) for COVID-19 and continued growth in its HIV franchise, particularly Biktarvy and Descovy for PrEP. Despite the revenue growth, net income attributable to Gilead saw a significant decrease to $123 million ($0.10 per diluted share) from $5.4 billion ($4.22 per diluted share) in 2019. This decline was largely attributed to substantial R&D expenses related to acquisitions (Forty Seven and Immunomedics), unfavorable changes in equity investment valuations (Galapagos), and a significant discrete tax benefit recorded in the prior year. The company continued its strategic expansion into oncology with the acquisition of Immunomedics, adding Trodelvy to its portfolio, and also made progress in its pipeline across various therapeutic areas. Looking ahead, Gilead expects continued growth from key products like Biktarvy and Trodelvy, which are expected to offset the impact of patent expirations for Truvada and Atripla. The company anticipates continued volatility in Veklury sales due to the dynamic COVID-19 landscape. Gilead remains focused on investing in its pipeline and expanding its therapeutic reach, particularly in oncology and inflammation, while prioritizing disciplined expense management and shareholder value. Investors should monitor the company's patent litigation outcomes, especially concerning Biktarvy, and the ongoing integration of its recent acquisitions.

Gilead Sciences, Inc.'s 2019 10-K filing highlights a year of solid financial performance, driven by continued growth in its HIV franchise, which accounted for approximately 74% of total product sales. Total revenues reached $22.4 billion, a slight increase from the prior year, primarily due to higher HIV product sales, notably Biktarvy, and increased use of Descovy for PrEP. The company also saw significant growth in its cell therapy business, Yescarta. However, sales for Hepatitis C (HCV) products declined due to lower pricing and patient starts, and older HIV products like Truvada saw decreased sales as patients shifted to newer TAF-based regimens and with the anticipation of generic competition. Gilead is actively positioning itself for future growth, aiming to launch 10 new transformative therapies by 2030. Key strategic moves in 2019 included a significant R&D collaboration with Galapagos NV, aimed at accelerating the development of treatments for inflammatory and fibrotic diseases, and progress in its oncology pipeline with Kite Pharma. The company's financial position remains strong, with substantial cash reserves, although R&D expenses increased significantly due to the Galapagos collaboration. Investors should monitor the company's ongoing pipeline development, particularly in inflammatory diseases and oncology, and remain aware of the potential impact of litigation, competition, and evolving healthcare regulations on future performance.

This document is an amendment to Gilead Sciences, Inc.'s 2018 Form 10-K filing, primarily detailing the exhibits and financial statement schedules included in the original report. For investors, this filing doesn't introduce new financial performance data or strategic updates for the 2018 fiscal year itself, but rather provides a comprehensive list of corporate governance documents, material contracts, and compensation plans. The included exhibits cover the company's charter and bylaws, various senior note indentures, a wide array of equity and deferred compensation plans for employees and directors, severance and bonus plans, significant license and collaboration agreements (including those related to Kite Pharma and Japan Tobacco), and subsidiary information. The certifications from the CEO and CFO reaffirm the accuracy of the original 10-K filing. Investors should refer to the original February 26, 2019 10-K filing for detailed financial performance, results of operations, and forward-looking statements. While this amendment doesn't contain new operational or financial results, it underscores the robust legal and contractual framework governing Gilead. The numerous exhibits related to employee and executive compensation, as well as significant partnership and licensing agreements, are key to understanding the company's long-term structure and strategic collaborations. The inclusion of detailed indentures for senior notes also provides insight into the company's debt obligations. Investors seeking a current view of Gilead's business strategy and financial health should consult the most recent filings and the original 10-K for the 2018 fiscal year.

Gilead Sciences, Inc. reported 2018 revenues of $22.1 billion, a decrease from $26.1 billion in 2017, primarily driven by a significant decline in Hepatitis C (HCV) product sales, which were down 60% to $3.7 billion. This was partially offset by a 12% increase in HIV product sales, reaching $14.6 billion, boosted by the strong performance of Biktarvy and other TAF-based regimens. The company made significant investments in research and development, increasing by 34% to $5.0 billion, including an $820 million impairment charge for the KITE-585 program. Gilead also advanced its cell therapy pipeline with the European Commission approval of Yescarta. The company's outlook for 2019 anticipates continued growth in HIV products and Truvada for PrEP, while expecting further declines in HCV sales, albeit at a slower rate. Gilead also announced a significant leadership transition with Daniel O'Day taking over as CEO.

Gilead Sciences, Inc. (GILD) reported significant financial and operational developments for the fiscal year ending December 30, 2017. The company experienced a notable decline in total revenues, primarily driven by a decrease in sales of its Hepatitis C Virus (HCV) products due to increased market competition. However, this was partially offset by strong performance in its HIV products, bolstered by the uptake of TAF-based regimens. A key strategic move was the acquisition of Kite Pharma, Inc. in October 2017, significantly expanding Gilead's presence in the promising field of cellular therapy, with the subsequent FDA approval of Yescarta™ for specific B-cell lymphomas. The company also made progress in its inflammation and respiratory pipeline, notably with filgotinib. Financially, Gilead reported a substantial increase in provision for income taxes, largely due to the Tax Cuts and Jobs Act enacted in late 2017. Despite the revenue dip, the company maintained a strong cash position, demonstrating robust operating cash flow and continuing its commitment to returning capital to shareholders through dividends and share repurchases.

Gilead Sciences, Inc. reported total revenues of $30.4 billion for the year ended December 31, 2016, a decrease of 7% compared to the prior year, primarily driven by a decline in Hepatitis C (HCV) product sales. Despite this, the company saw growth in its HIV franchise, largely due to the uptake of its new tenofovir alafenamide (TAF)-based regimens. Gilead also made significant progress in its R&D pipeline, advancing multiple candidates across its key therapeutic areas, including HIV, liver diseases, hematology/oncology, and inflammation/respiratory. The company ended 2016 with a strong balance sheet, holding $32.4 billion in cash, cash equivalents, and marketable securities. Gilead continued its commitment to returning capital to shareholders through significant share repurchases totaling $11.0 billion and dividend payments of $2.5 billion. However, the company faces increasing competition in the HCV market and potential headwinds from upcoming generic competition for its TDF-based HIV products. Significant litigation, particularly related to sofosbuvir, also presents a material risk, with potential damages estimated up to $8.5 billion if adverse outcomes are upheld on appeal.

Gilead Sciences, Inc. (GILD) reported a strong financial performance for the fiscal year ending December 31, 2015, with total revenues reaching $32.6 billion, a significant increase of 31% year-over-year. This growth was primarily driven by its antiviral products, particularly the Hepatitis C treatments Harvoni and Sovaldi, which accounted for a substantial portion of the revenue. The company also saw continued strength in its HIV franchise, supported by newer single-tablet regimens like Genvoya. While the company demonstrated robust revenue growth and profitability, it also highlighted ongoing investments in research and development, with R&D expenses increasing to $3.0 billion. Gilead's balance sheet remained strong, with cash, cash equivalents, and marketable securities totaling $26.2 billion. The company also returned significant capital to shareholders through share repurchases and initiated a quarterly dividend. Gilead faces a competitive market and ongoing pricing pressures, especially in the HCV segment, and is actively managing legal and patent challenges. The company provided an outlook for 2016, anticipating continued focus on pipeline progression and commercial uptake of its key products.

Gilead Sciences, Inc. reported significant growth in 2014, driven primarily by the successful launches of its Hepatitis C virus (HCV) treatments, Sovaldi and Harvoni. Total revenues surged to $24.9 billion, a substantial increase from $11.2 billion in 2013, with antiviral products accounting for the vast majority of sales. The company also saw strong performance from its HIV portfolio, particularly single-tablet regimens like Stribild and Complera/Eviplera. Despite the strong revenue growth, Gilead experienced a notable increase in operating expenses, including research and development (R&D) and selling, general, and administrative (SG&A) costs, largely due to investments in pipeline progression and expanding commercial infrastructure. The company ended the year with a robust cash position of $11.7 billion, underscoring its financial strength. Gilead also highlighted ongoing efforts to expand access to its medications in developing countries through licensing agreements. Looking ahead, Gilead anticipates continued net product sales growth, supported by expanded access to its HCV treatments and the potential launch of new HIV therapies. However, the company faces ongoing challenges including pricing pressures, competition in the HCV market, potential regulatory hurdles, and significant ongoing litigation related to its key products, particularly sofosbuvir.

Gilead Sciences, Inc.'s (GILD) 2013 10-K filing highlights a year of significant progress, particularly in its liver diseases and HIV segments. The company achieved FDA approval for Sovaldi (sofosbuvir), a groundbreaking treatment for Hepatitis C (HCV) that offers shorter treatment durations and improved efficacy compared to existing therapies. In HIV, Gilead expanded its single-tablet regimen (STR) offerings with the European launch of Stribild and approvals for its components, Tybost and Vitekta. The company also advanced its pipeline, with over 200 active clinical studies, including more than 60 Phase 3 trials. Financially, total revenues grew 15% to $11.20 billion, driven primarily by a 15% increase in product sales, reaching $10.80 billion. This growth was largely fueled by their antiviral products, especially the single-tablet regimens for HIV, such as Stribild and Complera/Eviplera. R&D expenses increased by 20% to $2.12 billion, reflecting continued investment in pipeline development. While SG&A expenses also rose, net income increased to $3.07 billion, or $1.81 per diluted share, up from $2.59 billion, or $1.64 per diluted share, in the prior year. Gilead also continued its commitment to shareholder returns through its stock repurchase program.

Gilead Sciences, Inc. (GILD) reported strong performance in its 2012 10-K filing, with total revenues reaching $9.7 billion, a 16% increase year-over-year, primarily driven by its antiviral franchise. The company highlighted significant strategic moves, including the $11.05 billion acquisition of Pharmasset to bolster its Hepatitis C (HCV) pipeline with sofosbuvir and the acquisition of YM Biosciences to expand its oncology/inflammation focus. Gilead also advanced its HIV portfolio with the U.S. launch of Stribild, a novel single tablet regimen, and the FDA approval of Truvada for pre-exposure prophylaxis (PrEP). The company demonstrated a commitment to expanding global access to its treatments, particularly for HIV and HBV in developing countries. Despite facing ongoing litigation with generic manufacturers and increasing competition, Gilead's robust R&D investment and strategic acquisitions positioned it for continued growth in key therapeutic areas.

Gilead Sciences, Inc. reported robust growth in its 2011 fiscal year, with total revenues reaching $8.39 billion, a 5% increase year-over-year, primarily driven by a 10% rise in product sales to $8.10 billion. The company's antiviral franchise, particularly sales of Atripla and Truvada, was the main growth engine. Gilead also made significant strategic moves, highlighted by the pending $11.1 billion acquisition of Pharmasset, Inc., aimed at strengthening its position in the hepatitis C market with the acquisition of the promising drug candidate GS-7977. The company is actively managing its pipeline, with advancements in HIV treatments including the submission of a new drug application for the 'Quad' single-tablet regimen and the launch of Complera/Eviplera. While facing increasing competition and ongoing pricing pressures, especially in Europe, Gilead demonstrated strong financial management, with a significant increase in cash reserves and continued stock repurchase programs. Investors should note the ongoing legal challenges related to patent defenses for key products and the potential impact of U.S. healthcare reform on future revenue and profitability.

Gilead Sciences, Inc. reported strong financial performance for the fiscal year ending December 31, 2010, with total revenues reaching $7.95 billion, a 14% increase year-over-year. This growth was primarily driven by its antiviral franchise, particularly Atripla and Truvada, which together accounted for 70% of total revenues. The company also saw significant contributions from its cardiovascular products, Letairis and Ranexa, and its newest respiratory product, Cayston, which demonstrated continued revenue growth. Gilead Sciences is actively managing its product pipeline through internal development and strategic acquisitions, with a notable focus on advancing its HIV and Hepatitis C drug candidates. The company's financial health is robust, supported by substantial operating cash flow and a significant cash balance. Gilead is also committed to returning value to shareholders through ongoing stock repurchase programs. However, investors should be aware of the company's reliance on its HIV products and the increasing competition in the HIV market, including the potential impact of generic drug introductions. Furthermore, changes in healthcare reform legislation in the U.S., potential pricing and reimbursement pressures in international markets, and ongoing patent litigation represent key risk factors that could impact future financial results.

Gilead Sciences, Inc. (GILD) reported strong revenue growth in its 2009 10-K filing, reaching $7.01 billion, a significant increase driven primarily by its antiviral products, notably Truvada and Atripla, which together represented 69% of total revenues. The company's strategic acquisition of CV Therapeutics in April 2009 expanded its presence in the cardiovascular therapeutic area, adding Ranexa to its portfolio. Gilead also demonstrated a commitment to global health through its Access Program, providing HIV medications at reduced prices in developing countries. Despite robust sales, the company faced challenges including increased R&D expenses, competition in its key markets, and potential impacts from foreign currency fluctuations and healthcare reforms. The company highlighted its strong pipeline progress, particularly in HIV with the evaluation of new combination therapies. Gilead's financial position remained solid, with substantial cash reserves and a continued focus on stock repurchases. The company's outlook for 2010 anticipated continued growth, supported by updated product labels, evolving treatment guidelines, and expanded commercial efforts, while acknowledging the uncertainties presented by the macroeconomic environment.

Gilead Sciences, Inc.'s 2008 annual report (10-K) highlights a year of significant growth, with total revenues reaching $5.34 billion, a 36% increase from 2007. This growth was primarily driven by strong performance in antiviral products, particularly Truvada and Atripla, which collectively generated $4.67 billion in sales. The company also saw substantial growth in its Letairis product for pulmonary arterial hypertension. Gilead's strong financial position is underscored by its increasing cash reserves and a substantial stock repurchase program. The company continues to invest heavily in research and development, with R&D expenses rising to $721.8 million, reflecting its commitment to expanding its pipeline of innovative therapeutics. Despite the robust financial performance, Gilead faces ongoing risks and challenges. The company's heavy reliance on its HIV product portfolio makes it vulnerable to shifts in treatment paradigms and increased competition, including potential generic challenges. Furthermore, reliance on a few major wholesale distributors for U.S. sales, inventory management complexities, and the potential impact of international currency fluctuations present operational risks. The company is also navigating regulatory hurdles, as demonstrated by the FDA's request for an additional clinical study for aztreonam for inhalation solution. Gilead's proactive approach to managing these risks, including strategic collaborations and a focus on pipeline development, positions it for continued engagement in addressing unmet medical needs.

Gilead Sciences, Inc. (GILD) reported robust growth in its 2007 annual filing, driven primarily by its HIV product portfolio, which represented 84% of total product sales. Truvada and the newly launched Atripla were key contributors, with total HIV product sales increasing by 48% year-over-year to $3.14 billion. The company also saw significant growth in Hepsera and AmBisome. Royalty revenues increased by 12%, largely from Tamiflu sales, though the company anticipates a decline in these royalties in 2008 due to anticipated lower Tamiflu sales by Roche. Looking ahead, Gilead is focused on expanding its international presence and advancing its pipeline, with new drug applications filed for Viread in Hepatitis B and aztreonam lysine for inhalation in cystic fibrosis. The company also highlighted its ongoing investment in research and development, which increased by 54% in 2007, signaling a commitment to future growth through innovation and strategic acquisitions. Despite strong revenue growth, investors should note the potential impact of increased competition, regulatory scrutiny, and pricing pressures in the pharmaceutical market.

Gilead Sciences, Inc. (GILD) reported strong performance for the fiscal year ending December 31, 2006, driven by significant growth in its HIV product portfolio, particularly Truvada and the newly launched Atripla. Total revenues reached $3.03 billion, a substantial increase from the previous year, fueled by a 43% rise in product sales to $2.59 billion. The company also saw a notable increase in royalty revenue, largely due to Tamiflu sales. Strategic acquisitions of Corus Pharma and Myogen in the respiratory and cardiopulmonary disease areas expanded Gilead's therapeutic focus beyond infectious diseases. The company continues to invest heavily in research and development, with expenses increasing by 38% in 2006 to support its diverse pipeline. Despite challenges such as increasing competition and the adoption of new accounting standards for stock-based compensation, Gilead demonstrated robust financial health and a clear strategy for future growth through both internal development and strategic acquisitions.

Gilead Sciences, Inc. reported substantial revenue growth in 2005, driven primarily by its HIV product portfolio, which accounted for 77% of total product sales. The company has successfully launched and gained market share for its key HIV treatments like Viread, Truvada, and Emtriva, demonstrating strong efficacy and safety profiles. Beyond HIV, Gilead is also seeing positive momentum in its Hepatitis B treatment Hepsera and antifungal drug AmBisome. Gilead's strategy involves both internal R&D and strategic acquisitions/in-licensing. The company made progress in developing treatments for Hepatitis C and strengthening its HIV pipeline. Financial highlights include significant increases in revenue, operating income, and cash flow. Gilead's robust financial position provides flexibility for future growth initiatives, including potential acquisitions and further R&D investments.

Gilead Sciences, Inc. (GILD) demonstrated strong growth in 2004, with total revenues reaching $1.32 billion, a significant increase from the previous year, driven primarily by its HIV product portfolio. The company's flagship HIV drugs, Viread, Emtriva, and the newly launched Truvada, collectively accounted for 73% of total product sales. Viread, in particular, showed robust performance with a 38% year-over-year revenue increase. Beyond its core HIV business, Gilead also maintained stable revenues for AmBisome, its antifungal treatment, despite increasing competition. The company is actively pursuing growth through strategic initiatives, including product acquisitions, in-licensing, and collaborations, such as the significant joint venture with Bristol-Myers Squibb to develop a once-daily HIV combination therapy. Gilead's financial health appears strong, with substantial cash reserves and positive operating cash flows, positioning it well for continued investment in research and development and potential future product launches.

Gilead Sciences, Inc.'s 2003 Form 10-K highlights a year of significant growth driven primarily by its HIV franchise, particularly Viread. The company reported total revenues of $867.9 million, with Viread contributing $566.5 million (65%) and AmBisome accounting for $210.9 million (24%). The acquisition of Triangle Pharmaceuticals in January 2003 for $525.2 million, largely allocated to in-process R&D, aimed to bolster Gilead's antiviral pipeline, notably adding Emtriva (emtricitabine) for HIV treatment and advancing potential hepatitis B therapies. Despite a substantial in-process R&D charge impacting operating results negatively for the year ($158.7 million operating loss), Gilead demonstrated robust operational cash flow ($234.6 million). The company is strategically focused on infectious diseases and is actively developing a fixed-dose combination of Viread and Emtriva, which is expected to enhance its HIV franchise. While facing increasing competition in its key markets, Gilead's strong product portfolio, ongoing R&D efforts, and strategic acquisitions position it for continued growth in the biopharmaceutical sector.

Gilead Sciences, Inc. (GILD) filed its 2002 Annual Report, highlighting significant revenue growth driven by its HIV treatment, Viread, which saw a substantial increase in sales following its U.S. approval in late 2001 and EU approval in early 2002. The company also reported continued strong performance from its antifungal drug, AmBisome, though anticipating increased competition. Significant strategic moves include the acquisition of Triangle Pharmaceuticals in January 2003, aimed at bolstering its antiviral pipeline, and the sale of its oncology assets to OSI Pharmaceuticals in late 2001 to sharpen its focus on infectious diseases. Gilead is actively managing its financial resources, including issuing convertible notes to strengthen its liquidity, while also navigating the complexities of global regulatory environments and international credit risks.

Gilead Sciences, Inc. reported significant revenue growth in 2002, driven primarily by the strong performance of Viread, an HIV treatment launched in late 2001. Total revenues reached $466.8 million, a substantial increase from $233.8 million in 2001, with Viread sales accounting for 53% of product sales. While AmBisome, an antifungal, also contributed significantly, its sales growth slowed, and declining U.S. sales were offset by European growth. The company completed the acquisition of Triangle Pharmaceuticals in January 2003, indicating a strategic focus on expanding its product pipeline, particularly in antivirals. The company ended 2002 with a strong liquidity position, holding $942.4 million in cash, cash equivalents, and marketable securities. This was bolstered by a $345 million issuance of convertible senior notes. Despite investments in R&D and sales/marketing to support new product launches and market expansion, Gilead demonstrated improving operational profitability, moving from an operating loss in 2001 to an operating income of $81 million in 2002. The company's financial health appears robust, with a clear focus on growth through its key infectious disease treatments and strategic acquisitions.

Gilead Sciences, Inc. reported robust revenue growth in 2002, driven primarily by strong sales of Viread, its HIV treatment, which nearly doubled its revenue contribution compared to 2001. AmBisome, an antifungal, also showed solid growth, contributing significantly to the company's overall performance. The company's acquisition of Triangle Pharmaceuticals in January 2003 marked a strategic move to bolster its antiviral pipeline, particularly for HIV and Hepatitis B, with the inclusion of emtricitabine and other promising drug candidates. Financially, Gilead achieved operating profitability in 2002 after years of losses, indicating a positive trajectory. However, the company faces ongoing challenges, including increasing competition in key therapeutic areas and the complexities of integrating new acquisitions. Gilead also highlighted its commitment to global health initiatives, announcing plans to supply Viread at cost to developing countries, demonstrating a balance between commercial objectives and social responsibility.

Gilead Sciences, Inc. reported significant revenue growth for the fiscal year ended December 31, 2001, reaching $233.8 million. This growth was primarily driven by its antifungal drug, AmBisome, which accounted for 78% of total revenues, generating $181.6 million. The company also saw initial sales from Viread, its HIV treatment, which was approved in the U.S. in October 2001 and the EU in February 2002. A key strategic move was the sale of its oncology assets to OSI Pharmaceuticals in December 2001 for up to $200 million, allowing Gilead to sharpen its focus on infectious diseases. Financially, Gilead remains in an investment phase, reporting a net loss for the year due to substantial research and development expenses, which totaled $185.6 million. The company ended the year with a strong cash position of $582.9 million, indicating healthy liquidity to fund ongoing development and potential future acquisitions. Investors should note the company's reliance on AmBisome and the critical role Viread is expected to play in future revenue generation and its competitive landscape.

Gilead Sciences, Inc.'s 2000 10-K report highlights a period of significant revenue growth, primarily driven by its leading antifungal drug, AmBisome. Total revenues reached $195.6 million, a substantial increase from the previous year, with AmBisome contributing over 70% of product sales. The company is actively expanding its pipeline, with a notable focus on tenofovir DF for HIV treatment, which has shown promising Phase III trial results and is slated for regulatory submission in mid-2001. Additionally, Gilead is advancing adefovir dipivoxil for Hepatitis B and exploring oncology treatments. The company's financial performance reflects ongoing investment in research and development, leading to net losses, but a strong cash position of over $512 million provides ample resources for future development and potential acquisitions. The report also emphasizes Gilead's strategic collaborative relationships, particularly with Hoffmann-La Roche for Tamiflu and Fujisawa Healthcare for AmBisome, which are crucial for both revenue generation and market reach. While acknowledging competitive pressures and the inherent risks in drug development, Gilead appears strategically positioned with a diversified product portfolio and a robust pipeline, supported by its expertise in liposomal drug delivery technology.